<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5814">
  <stage>Registered</stage>
  <submitdate>24/03/2016</submitdate>
  <approvaldate>24/03/2016</approvaldate>
  <nctid>NCT02731911</nctid>
  <trial_identification>
    <studytitle>Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study</studytitle>
    <scientifictitle>Phase 4, Open-label, Non-randomized, Prospective Study of OZURDEX® in the Treatment of Diabetic Macular Oedema - The AUSSIEDEX Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CMO-AP-EYE-0438</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Macular Oedema</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - dexamethasone intravitreal implant

Ozurdex® (dexamethasone intravitreal implant) - Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.


Treatment: drugs: dexamethasone intravitreal implant
Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean change in Best Corrected Visual Acuity (BCVA) from baseline</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Mean change in Central Retinal Thickness (CRT) from baseline</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with a BCVA improvement of 15 letters or more</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with a BCVA improvement of 10 letters or more</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BCVA average mean from baseline in area under the curve (AUC) analysis</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Intraocular Pressure (IOP)-lowering treatments used to control IOP increase</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean BCVA at each injection number</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change from baseline in BCVA at each injection number</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in BCVA across all the study injection numbers</outcome>
      <timepoint>Baseline, 12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with BCVA improvement</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of BCVA losers</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients improving to 20/40 or better</outcome>
      <timepoint>Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean number of Ozurdex injections</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean interval between Ozurdex® injections</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in central subfield retinal thickness by Optical Coherence Tomography (OCT) before each follow-up injection number</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Pseudophakic or phakic and scheduled for a cataract operation

          -  Macular oedema due to DME</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous Ozurdex® treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>29/04/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/09/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Retina and Macula Specialists,Hurstville - Hurtsville</hospital>
    <hospital>Retina Associates - Liverpool</hospital>
    <hospital>Retina and Macula Specialists, Miranda - Miranda</hospital>
    <hospital>Eye Doctors Mona Vale - Mona Vale</hospital>
    <hospital>Marsden Eye Clinic - Parramatta</hospital>
    <hospital>Retina &amp; Vitreous Centre Strathfield - Strathfield</hospital>
    <hospital>Strathfield Retina - Strathfield</hospital>
    <hospital>Retina &amp; Vitreous Centre City - Sydney</hospital>
    <hospital>Sydney Eye and Retina Clinic - Sydney</hospital>
    <hospital>Sydney Eye Hospital/Macular Diseases Centre - Sydney</hospital>
    <hospital>Sydney West Retina - Westmead</hospital>
    <hospital>Terrace Eye Centre - Brisbane</hospital>
    <hospital>Caboolture Eye Surgery - Caboolture</hospital>
    <hospital>Peninsula Eye Hospital - Redcliffe</hospital>
    <hospital>The Qld Eye Institute - South Brisbane</hospital>
    <hospital>Adelaide Eye &amp; Retina Centre - Adelaide</hospital>
    <hospital>Department of Opthalmology, Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Hobart Eye Surgeons - Hobart</hospital>
    <hospital>Tasmanian Eye Institute - Launceston</hospital>
    <hospital>Essendon Retina - Essendon</hospital>
    <hospital>Victoria Parade Eye Consultants - Fitzroy</hospital>
    <hospital>Vision Eye Institute - Footscry</hospital>
    <hospital>Lions Eye Institute - Nedlands</hospital>
    <postcode>2220 - Hurtsville</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2228 - Miranda</postcode>
    <postcode>2103 - Mona Vale</postcode>
    <postcode>2150 - Parramatta</postcode>
    <postcode>2135 - Strathfield</postcode>
    <postcode>2000 - Sydney</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4000 - Brisbane</postcode>
    <postcode>4510 - Caboolture</postcode>
    <postcode>4020 - Redcliffe</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5000 - Hobart</postcode>
    <postcode>7249 - Launceston</postcode>
    <postcode>3040 - Essendon</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3011 - Footscry</postcode>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in
      clinical practice.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02731911</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. George Labib</name>
      <address>Allergan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Trials Registry Team</name>
      <address />
      <phone>1-800-347-4500</phone>
      <fax />
      <email>IR-CTRegistration@allergan.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>